Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Perioperative treatment approaches for gastroesophageal cancers

Nataliya Uboha • 6 Jun 2022
ASCO 2022
Esophageal Cancer Gastric Cancer Gastroesophageal Cancer Gastrointestinal Cancer Antibodies Avelumab Ipilimumab Nivolumab

Nataliya Uboha, MD, PhD, University of Wisconsin, Madison, WI, discusses perioperative treatment approaches for esophageal cancer, gastroesophageal junction cancer, and gastric cancer, including current standards of care and future therapeutic possibilities. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Nataliya Uboha

2:45
Current and future biomarkers for gastroesophageal cancer
Nataliya Uboha • 27 Mar 2023
0:48
FGFR2b: a novel biomarker for patients with gastroesophageal cancer
Nataliya Uboha • 27 Mar 2023
1:08
The role of neoadjuvant immunotherapy in MSI-high gastric cancer
Nataliya Uboha • 20 Jan 2023
1:44
What role will zolbetuximab play in treating gastric cancer?
Nataliya Uboha • 20 Jan 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals